SCHEMBL7908133

SCHEMBL7908133

CC(C)C(NC(=O)C1(c2ccc(F)cc2)CCN(C(=O)c2ccc(N3CCCCC3=O)cc2)CC1)c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.47
ALDH1A1 P00352 3/20 0.47
TACR3 P29371 2/20 0.44
LMNA P02545 2/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HSD11B1 P28845 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
F10 P00742 1/20 0.39
KCNK3 O14649 1/20 0.39
ACACB O00763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7909991 0.91 HPGD (0.49) HPGDALDH1A1TACR3LMNACYP1A2
SCHEMBL7913743 0.87 HPGD (0.48) HPGDALDH1A1TACR3LMNACYP1A2
SCHEMBL7908251 0.85 MAPT (0.42) HSD11B1MAPTMEN1KMT2ATSHR
SCHEMBL7910241 0.85 CYP2D6 (0.47) HPGDALDH1A1TACR3LMNACYP1A2
SCHEMBL7914347 0.82 ALDH1A1 (0.45) HPGDALDH1A1TACR3LMNACYP1A2
SCHEMBL379014 0.82 ALDH1A1 (0.58) HPGDALDH1A1TACR3LMNAKDM4E
SCHEMBL7907121 0.82 ALDH1A1 (0.53) HPGDALDH1A1TACR3LMNAKDM4E
SCHEMBL378786 0.81 MEN1 (0.46) HPGDHSD11B1MEN1KMT2ATSHR
SCHEMBL13092236 0.80 CYP1A2 (0.61) HPGDALDH1A1LMNACYP1A2CYP2D6
SCHEMBL13092455 0.80 ALDH1A1 (0.43) HPGDALDH1A1TACR3LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 HPGD 1256/4885ALDH1A1 480/4885TACR3 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.